Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients.

@article{Vtko2004Everolimus1,
  title={Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients.},
  author={Stefan V{\'i}tko and Raimund Margreiter and Willem W Weimar and Jacques Dantal and Hendrik G Viljoen and Yulan Li and Annette Jappe and Nathalie Cretin},
  journal={Transplantation},
  year={2004},
  volume={78 10},
  pages={
          1532-40
        }
}
BACKGROUND Everolimus is a proliferation inhibitor designed to target chronic rejection, including prevention of acute rejection. Everolimus blocks growth factor-mediated transduction signals, preventing organ rejection by a mechanism different than that of calcineurin inhibitors and of mycophenolate mofetil (MMF). METHODS.: Everolimus (1.5 mg or 3 mg daily) was compared with MMF (2 g daily) in a randomized, multicenter, multinational, 12-month double-blind, double-dummy and 2-year open-label… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 63 CITATIONS

FILTER CITATIONS BY YEAR

2005
2017

CITATION STATISTICS

  • 6 Highly Influenced Citations

  • Averaged 3 Citations per year over the last 3 years

Similar Papers

Loading similar papers…